Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 1/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11671840 | 0.76 | NR1I3 (0.50) | NR1I3AKR1B10CDK5CDK5R1 | |
| SCHEMBL11672190 | 0.76 | NR1I3 (0.50) | NR1I3AKR1B10CDK5CDK5R1 | |
| SCHEMBL11673103 | 0.76 | NR1I3 (0.50) | NR1I3AKR1B10CDK5CDK5R1 | |
| SCHEMBL11671836 | 0.76 | NR1I3 (0.50) | NR1I3AKR1B10CDK5CDK5R1 | |
| SCHEMBL11672814 | 0.76 | NR1I3 (0.50) | NR1I3AKR1B10CDK5CDK5R1 | |
| SCHEMBL6377763 | 0.76 | NR1I3 (0.39) | NR1I3AKR1B10CDK5CDK5R1GRIN1 | |
| SCHEMBL3825 | 0.76 | CDK5 (0.40) | NR1I3CDK5CDK5R1GRIN1GRIN2B | |
| SCHEMBL901326 | 0.76 | CDK5 (0.40) | NR1I3CDK5CDK5R1GRIN1GRIN2B | |
| SCHEMBL332530 | 0.76 | CDK5 (0.40) | NR1I3CDK5CDK5R1GRIN1GRIN2B | |
| SCHEMBL1480601 | 0.75 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298754-B9 | Preparation of taxane derivatives | INDENA SPA (IT) | 2013-12-18 | — | — | EP | disclosed |
| EP-2298754-B1 | Preparation of taxane derivatives | INDENA SPA (IT) | 2013-08-07 | — | — | EP | disclosed |
| EP-2264019-B1 | Intermediates for the preparation of taxane derivatives | INDENA SPA (IT) | 2013-07-24 | — | — | EP | disclosed |
| EP-2077264-B1 | Taxane derivatives and a process for the preparation thereof | INDENA SPA (IT) | 2012-11-14 | — | — | EP | disclosed |
| EP-2298754-A1 | Preparation of taxane derivatives | Indena S.p.A. (IT) | 2011-03-23 | — | — | EP | disclosed |
| EP-2281820-A2 | Taxane derivatives and a process for the preparation thereof | Indena S.p.A. (IT) | 2011-02-09 | — | — | EP | disclosed |
| EP-2264019-A1 | Intermediates fot the preparation of taxane derivatives | Indena S.p.A. (IT) | 2010-12-22 | — | — | EP | disclosed |
| EP-2077264-A2 | Taxane derivatives and a process for the preparation thereof | INDENA S.p.A. (IT) | 2009-07-08 | — | — | EP | disclosed |
| US-7498452-B2 | Taxane derivatives functionalized at the 14-position and a process for the preparation thereof | INDENA S.P.A. (IT) | 2009-03-03 | — | — | US | disclosed |
| EP-1980557-A2 | Taxane derivatives functionalized at the 14-position and a process for the preparation thereof | Indena S.P.A. (IT) | 2008-10-15 | — | — | EP | disclosed |
| EP-1537093-B1 | TAXANE DERIVATIVES FUNCTIONALIZED AT THE 14- POSITION AND A PROCESS FOR THE PREPARATION THEREOF | INDENA SPA (IT) | 2008-06-11 | — | — | EP | disclosed |
| US-20060122258-A1 | Taxane derivatives functionalized at the 14-position and a process for the preparation thereof | INDENA S.P.A. (IT) | 2006-06-08 | — | — | US | disclosed |
| EP-1537093-A2 | TAXANE DERIVATIVES FUNCTIONALIZED AT THE 14- POSITION AND A PROCESS FOR THE PREPARATION THEREOF | INDENA S.p.A. (IT) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004024706-A2 | TAXANE DERIVATIVES FUNCTIONALIZED AT THE 14- POSITION AND A PROCESS FOR THE PREPARATION THEREOF | INDENA S.P.A. (IT) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122258-A1 | Taxane derivatives functionalized at the 14-position and a process for the preparation thereof | TUBA1B, TUBB2B, TUBB3 | NR1I3 2851/4885AKR1B10 52/4885CDK5 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.